AEON Biopharma Appoints Industry Veteran Rob Bancroft as CEO

Irvine, CA, April 23, 2025 (Globe Newswire) -- AEON Biopharma has named Rob Bancroft as its new CEO as it accelerates development of ABP-450, a biosimilar to BOTOX. Bancroft brings extensive industry experience, including leading the therapeutic launch of Daxxify® at Revance and holding senior roles at Allergan. His appointment underscores AEON’s strategic push to position ABP-450 as a broad-market biosimilar, with key regulatory updates expected later in 2025.

Read full article here.